Shapuaisi released its 2026 interim report, with total operating revenue of 197 million yuan, down 16.77% year-on-year. Net profit attributable to the parent company was 19.5003 million yuan, down 10.81% from the same period last year. Net cash inflow from operating activities was 910,100 yuan, a sharp year-on-year decline of 98.23%. The company's asset-liability ratio was 24.24% and gross margin was 50.80%, both changed from the same period last year. Diluted earnings per share were 0.05 yuan, down 16.67% year-on-year.
Zhejiang Shapuaisi Pharmaceutical Co LtdNet profit down 10.81% and operating cash flow down 98.23% in interim report.